Detailed Information on Publication Record
2020
The role of MYC in the transformation and aggressiveness of ?indolent? B-cell malignancies
FILIP, Daniel and Marek MRÁZBasic information
Original name
The role of MYC in the transformation and aggressiveness of ?indolent? B-cell malignancies
Authors
FILIP, Daniel (703 Slovakia, belonging to the institution) and Marek MRÁZ (203 Czech Republic, guarantor, belonging to the institution)
Edition
LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2020, 1042-8194
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.280
RIV identification code
RIV/00216224:14740/20:00118594
Organization unit
Central European Institute of Technology
UT WoS
000491844800001
Keywords in English
Lymphomas; indolent mature B-cell malignancies; transformation; MYC; microRNA
Tags
International impact, Reviewed
Změněno: 12/5/2021 12:44, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
MYC was found to be involved in many germinal center derived lymphomas, and more recently in the histological transformation of indolent mature B-cell malignancies, such as follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) and mucosa-associated lymphoid tissue lymphoma (MALT) to aggressive diffuse large B-cell lymphoma (DLBCL). Pathological MYC activity gain in lymphomas is able to overcome its regulation by repressors, which leads to bypassing the affinity-based selection of B-cells. Arguably the MYC activity gain is the most constantly observed phenomenon (>70% of cases) in transformed FL/MALT/CLL (Richter?s transformation) and co-occurs with specific aberrations such as the loss of p53, CDKN2A/B, or gain of BCL2/BCL6. Here we summarize recent progress in the understanding of MYC regulatory network in lymphoma B-cells and highlight its involvement in lymphomas? histological transformation by regulating cyclins, CDKs, p21, p27, BCL2, E2F, FOXP1, BCR signaling components, and non-coding microRNA (miRNA) genes such as miR-150, miR-29, miR-17-92, and miR-34a.
Links
NV18-03-00054, research and development project |
|